Table 1.
Preclinical development of DNA vaccines against SARS-CoV-2.
| Name of Vaccine | Developer | Plasmid vector | Main antigenic region | Adjuvant | Mode of Administration | Reference |
|---|---|---|---|---|---|---|
| INO-4800 | Inovio Pharmaceuticals | pGX0001 | full length S gene | – | Electroporation using CELLECTRA® delivery device | [10] |
| SARS-CoV-2 DNA vaccine tested in Syrian hamsters | Taiwan Group | pVAX1 | spike genes of SARS-CoV and SARS-CoV-2 | – | Intramuscular electroporation with a BTX electroporator (ECM830) | [11] |
| DNA Vaccine candidates developed by Chulalongkorn University | Thailand Group | pCMVkan | full length S, S1, and S2 | – | Intramuscular electroporation using TriGrid delivery system | [12] |
| SARS-CoV-2 Spike glycoprotein DNA plasmid vaccine | Osaka University (Japan group) | pVAX1 | full length S gene | alum | Intramuscular injection | [20] |
| IgE-spike-S1/S2-D614G-6P-foldon | Southern University of Science and Technology, China | PCDNA3.1 | S-protein S1+S2 | – | Intramuscular injection | [31] |
| pSARS2-S | National Institute of Infectious Diseases and Vaccinology Taiwan | pVAX1 | full length S gene | alum | Electroacupuncture | [32] |
| VIU-1005 | King Abdulaziz University | pVAX1 | full length S gene | – | intramuscular needle injection | [26] |
| pVAX-S1 | King Abdulaziz University | pVAX1 | S1 subunit | – | intramuscular administration using customized needle-free Tropis system | [27] |
| pVAX1-SARS-CoV2-co | Osaka University | pVAX1 | S protein | – | Intradermal using a pyro-drive jet injector | [28] |